31.9 F
New York
Friday, December 2, 2022

Date:

Share:

Gallant Announces Hiring of John Klacking, Ph.D. as Chief Business Officer

Related Articles

San Diego, CA, October 25, 2022 –(PR.com)– Gallant Therapeutics, an animal health biotechnology company developing stem cell therapies for pets, welcomes John Klacking, Ph.D., as Chief Business Officer. Dr. Klacking, founder of Angiocrine Bioscience, brings thirty years of experience in finance and business development to the company.

Dr. Klacking founded Angiocrine Bioscience, a stem cell therapeutic company, with Shahin Rafi at Cornell Weill Medical Center in New York City. Prior to that, he founded Angelica Therapeutics, a San Francisco Bay Area cancer-focused biotech company. Dr. Klacking began his career in the consulting group of EF Hutton which merged into Salomon Smith Barney as a Senior Vice President from 1987-2006.

“John, with his deep finance and business development background, is a great addition to our leadership team,” says Linda Black, DVM, Ph.D., CEO. “I look forward to partnering with John to strategically…

Read more…

Popular Articles